N/A N=100 Impact of Pharmaceutical Care in Diabetics Patients
Diabetes Mellitus Type 2
Primary: Glycated Hemoglobin — 7.2; 7.1 percent (%)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=569 A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival (PFS) — 18.43; NA months
Phase 2 N=25 OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation
Malaria
Primary: Minimum Inhibitory Concentration (MIC) and Minimum Parasiticidal Concentration (MPC) — 2.4; 4.1; 77; 319 ng/Ml
Phase 2 N=88 Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: MATRICS Consensus Cognitive Battery (MCCB) — 30.92; 30.32; 33.43; 32.76 T score
Phase 3 N=68 A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
Lung Transplantation
Primary: Maximum Concentration (Cmax) of Mycophenolic Acid (MPA), Mycophenolic Acid Glucuronide (MPAG) and Acyl Glucuronide Metabolite of Mycophenolic Acid (AcMPAG) at Day 4…
Phase 3 N=660 Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.
Tetanus · Diphtheria · Acellular Pertussis
Primary: Number of Seroprotected Subjects Against Diphteria Toxoid (D) and Tetanus Toxoid (T) — 162; 164; 163; 164 Subjects
Phase 2 N=70 BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Mean Change From Baseline in 7-Point Glucose Monitoring (7-PGM) at Day 7 — -16.52; -19.01; -17.29; -23.40 mg/dL
Phase 3 N=182 Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis
Pediatric Plaque Psoriasis
Primary: Number of Participants With Adverse Events — 161; 149; 140; 14 participants
Phase 3 N=498 Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival (PFS) — 7.16; NA months
Phase 2 N=63 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Marginal Zone Lymphoma · B-cell Lymphoma
Primary: ORR (Overall Response Rate) — 46 Percentage of Participants
Phase 3 N=1,170 Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Type 2 Diabetes
Primary: Change in HbA1c From Baseline to Week 30 — -1.63; -1.34; -0.85 percentage of hemoglobin — p=<0.0001
Phase 2 N=50 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029
Phase 2 N=323 Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -1.82; -1.64 percentage of hemoglobin — p=0.0130
N/A N=180 Variability in Perimetry Study
Glaucoma
Primary: Number of Subjects Progressing in Each Group Using Pointwise Linear Regression — 0; 0 participants — p=.21
Phase 3 N=252 Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
Diabetes Mellitus, Type 2
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF] — -0.32; -0.41; -0.44 % of hemoglobin — p=0.561